Original Research Article
Year: 2018 | Month: October | Volume: 5 | Issue: 10 | Pages: 439-446
Metabolic Syndrome with Drug Olanzapine: A Comparison between Standard and Orally Disintegrating Tablets
Dr. Ashish Kumar Malik1, Dr. Deepika Dalal2, Dr. Kiran Dahiya3, Dr. Prateek Kumar4, Dr. Savinder Singh5, Dr. Asha Kumari6
1Senior Resident, Department of Psychiatry, PGIMS, Rohtak
2Demonstrator, 3Professor, Department of Biochemistry, PGIMS, Rohtak
4DNB, Department of Psychiatry, IMH, Amritsar
5Director, IMH, Amritsar
6Assistant Professor, Department of Biochemistry, SHKM GMC, Nalhar, Haryana, India.
Corresponding Author: Dr. Asha Kumari
ABSTRACT
Objective: To compare drug emergence metabolic syndrome between patients taking standard olanzapine tablet (OST) versus orally disintegrating olanzapine (ODO) tablet.
Methods: Eighty patients receiving olanzapine were divided into two equal groups of OST and ODO formulation. They were assessed for metabolic syndrome along with parameters like body weight, body mass index (BMI), waist circumference, blood pressure, fasting serum glucose, triglyceride (TG) and high density lipoprotein cholesterol (HDL-C) at 0, 2 and 4 months of starting the drug. All the results were compared using appropriate statistical analysis.
Results: An increase in body weight, BMI, waist circumference, blood pressure, fasting glucose, TG and a decrease in HDL-C was observed in both the groups at baseline, 2 and 4 months although the difference between the two groups was not found to be significant (p>0.05). The change in each parameter after 4 months between two groups was also not found to be significant (p>0.05). Drug emergent metabolic syndrome at 4 months of starting the therapy was 22.5% in OST group as compared to 17.5% in ODO group.
Conclusion: No significant difference was observed between oral disintegrating tablet and standard olanzapine tablet in terms of derangements in metabolic parameters and emergence of metabolic syndrome.
Key words: oral disintegrating olanzapine; standard olanzapine tablet; syndrome X; schizophrenia; metabolic syndrome.
[PDF Full Text]